Canaan XI L.P. - Sep 13, 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
10%+ Owner
Signature
Canaan XI L.P., By: Canaan Partners XI LLC, its general partner, By: /s/ Nancy Levenson, Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Sep 13, 2022
Transactions value $
-$5,823,084
Form type
4
Date filed
9/15/2022, 07:48 PM
Previous filing
Dec 22, 2021
Next filing
Sep 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Sale -$2.11M -86.6K -0.9% $24.39 9.58M Sep 13, 2022 Direct F1, F2
transaction DAWN Common Stock Sale -$25.1K -1K -0.01% $25.01 9.58M Sep 13, 2022 Direct F2, F3
transaction DAWN Common Stock Sale -$2.5M -106K -1.1% $23.68 9.47M Sep 14, 2022 Direct F2, F4
transaction DAWN Common Stock Sale -$9.33K -384 0% $24.29 9.47M Sep 14, 2022 Direct F2, F5
transaction DAWN Common Stock Sale -$1.09M -48K -0.51% $22.79 9.42M Sep 15, 2022 Direct F2, F6
transaction DAWN Common Stock Sale -$78.6K -3.31K -0.04% $23.73 9.42M Sep 15, 2022 Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 - $24.99, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 - $25.06, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.25 - $24.23, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 Price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.28 - $24.29, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 - $23.52, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.55 - $24.01, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.